Icatibant (Firazyr®)
Icatibant (Firazyr®) indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE).
Rapid Review
| Commenced | Completed | Outcome |
| 22 July 2013 | 31 July 2013 | Full pharmacoeconomic evaluation not recommended |